Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a multicenter, retrospective, observational real-world study designed based on real-world data. Eligible medical institutions that meet standardized data quality requirements and have an adequate sample size will be enrolled in this study. The treatment group consists of patients with completely resected (R0) stage IA2 high-risk to IB non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations who received adjuvant icotinib therapy after radical resection. The control group includes patients with completely resected (R0) stage IA2 high-risk to IB NSCLC with positive EGFR-sensitizing mutations who received routine observational follow-up after surgery. Propensity score-matched analyses will be conducted between the treatment and control groups to evaluate the efficacy and safety of adjuvant icotinib therapy in this patient population.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie rak płuc typu niedrobnokomórkowego (głównie gruczolakorak)
- •Etap zaawansowania IA2 (wysoki риск) do IB po całkowitym chirurgicznym usunięciu guza
- •Obecność mutacji EGFR w pobranym podczas operacji materiale
- •W grupie kontrolnej: pacjenci po operacji, którzy nie otrzymali żadnego leczenia przeciwnowotworowego
✗ Disqualifies
- •Inne nowotwory złośliwe w ciągu 5 lat przed operacją (z wyjątkiem wyleczonych)
- •Wcześniejsze leczenie systemowe raka płuc w ciągu 6 miesięcy przed operacją
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Beijing Cancer Hospital
Beijing, China
Shanghai Pulmonary Hospital
Shanghai, China
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.